Literature DB >> 9365329

Incidental pituitary macroadenoma: a population-based study.

G M Nammour1, J Ybarra, M H Naheedy, J H Romeo, D C Aron.   

Abstract

Epidemiologic analysis of incidental macroadenoma is limited to autopsy studies and case series. There are no published data about prevalence of incidental pituitary macroadenoma in living patients. The objective of this study was to determine the prevalence of incidental pituitary macroadenoma. It was designed as an observational study of cranial computed tomography reports. An urban department of veterans affairs medical center was used for the setting. The subject group consisted of 3,550 consecutive patients at the Cleveland Department of Veterans Affairs Medical Center from January 1993 to January 1996. Patients with known or suspected pituitary or parasellar disease were excluded. Cranial computed tomography reports were reviewed. Original films and medical charts of all patients with pituitary macroadenoma were reviewed. Seven patients with incidentally discovered pituitary macroadenoma that ranged from 1 cm to 2.5 cm were found; prevalence was 0.20% (95% confidence interval 0.05, 0.35%). Evidence of partial hypopituitarism was found in most patients. All patients had normal visual fields at initial examination despite the size of the tumor, but 1 of 4 had a field cut demonstrated by Goldmann perimetry. These data confirm that, although the prevalence of incidental pituitary macroadenoma is low, screening identified patients to detect deficiency of corticotropin, thyroid-stimulating hormone, and gonadotropins and to detect visual field defects is important.

Entities:  

Mesh:

Year:  1997        PMID: 9365329     DOI: 10.1097/00000441-199711000-00003

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  17 in total

1.  Spontaneous regression of one nonfunctioning pituitary macroadenoma associated with abnormal liver enzyme tests.

Authors:  Adele Bahar; Zahra Kashi; Arezoo Nowzari
Journal:  Caspian J Intern Med       Date:  2011

2.  A pilot genome-scale profiling of DNA methylation in sporadic pituitary macroadenomas: association with tumor invasion and histopathological subtype.

Authors:  Chao Ling; Matthew Pease; Lingling Shi; Vasu Punj; Mark S Shiroishi; Deborah Commins; Daniel J Weisenberger; Kai Wang; Gabriel Zada
Journal:  PLoS One       Date:  2014-04-29       Impact factor: 3.240

Review 3.  Endocrine incidentalomas--challenges imposed by incidentally discovered lesions.

Authors:  Dimitra A Vassiliadi; Stylianos Tsagarakis
Journal:  Nat Rev Endocrinol       Date:  2011-06-28       Impact factor: 43.330

Review 4.  Pituitary incidentalomas.

Authors:  George A Scangas; Edward R Laws
Journal:  Pituitary       Date:  2014-10       Impact factor: 4.107

5.  The association of pituitary tumors and headache.

Authors:  Miles J Levy
Journal:  Curr Neurol Neurosci Rep       Date:  2011-04       Impact factor: 5.081

Review 6.  [Clinical magnetic resonance imaging : Frequent incidental cerebral findings].

Authors:  A Müller; P Ditter; S Weidauer; H-H Schild; E Hattingen
Journal:  Radiologe       Date:  2017-04       Impact factor: 0.635

Review 7.  Biochemical Testing of the Thyroid: TSH is the Best and, Oftentimes, Only Test Needed - A Review for Primary Care.

Authors:  Michael T Sheehan
Journal:  Clin Med Res       Date:  2016-05-26

Review 8.  Epidemiology and etiopathogenesis of pituitary adenomas.

Authors:  Elena D Aflorei; Márta Korbonits
Journal:  J Neurooncol       Date:  2014-01-31       Impact factor: 4.130

9.  Pituitary imaging findings in male patients with hypogonadotrophic hypogonadism.

Authors:  Dania Hirsch; Carlos Benbassat; Yoel Toledano; Irena S'chigol; Gloria Tsvetov; Ilana Shraga-Slutzky; Yoav Eizenberg; Ilan Shimon
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

10.  The presence of a pituitary tumor in patients with prostate cancer is not a contraindication for leuprolide therapy.

Authors:  Angela Babbo; George T Kalapurakal; Benjamin Liu; Sanija Bajramovic; James P Chandler; John Garnett; John A Kalapurakal
Journal:  Int Urol Nephrol       Date:  2014-04-06       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.